Genetic variation and risk of chronic lymphocytic leukaemia

Seminars in Cancer Biology

Volumn 20, Issue 6, 2010, Pages 363-369

  Crowther Swanepoel, Dalemari ^a   Houlston, Richard S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

CLL; Genetic; Inherited; Susceptibility

Indexed keywords

FAR UPSTREAM ELEMENT BINDING PROTEIN INTERACTING REPRESSOR; IMMUNOGLOBULIN HEAVY CHAIN; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR 4; MICRORNA; MYC PROTEIN; NUCLEAR PROTEIN; POLYCYSTIN 2; PROTEIN BCL 2; PROTEIN MDM2; REPRESSOR PROTEIN; SP140 PROTEIN; TRANSCRIPTION FACTOR PU 1; UBIQUITIN PROTEIN LIGASE NEDD4; UNCLASSIFIED DRUG;

ALLELE; B CELL LYMPHOCYTOSIS; B LYMPHOCYTE; CANCER RISK; CANCER SUSCEPTIBILITY; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 15Q; CHROMOSOME 2Q; CHROMOSOME 8Q; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; EPIDEMIOLOGICAL DATA; FAMILY HISTORY; FAMILY STUDY; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOGLOBULIN STRUCTURE; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMOGENESIS; LYMPHOCYTOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRISOMY 12;

CHROMOSOME ABERRATIONS; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RISK FACTORS;

EID: 78649783882     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2010.08.006     Document Type: Review

References (86)

1. Ries L.A., Wingo P.A., Miller D.S., Howe H.L., Weir H.K., Rosenberg H.M., et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 2000, 88:2398-2424.
2. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, et al. In: Edwards BK, editor. SEER cancer statistics review, 1975-2006. Bethesda; 2009.
3. Gale R.P., Cozen W., Goodman M.T., Wang F.F., Bernstein L. Decreased chronic lymphocytic leukemia incidence in Asians in Los Angeles County. Leuk Res 2000, 24:665-669.
4. Haenszel W., Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 1968, 40:43-68.
5. Cobb R.M., Oestreich K.J., Osipovich O.A., Oltz E.M. Accessibility control of V(D)J recombination. Adv Immunol 2006, 91:45-109.
6. Chung J.B., Silverman M., Monroe J.G. Transitional B cells: step by step towards immune competence. Trends Immunol 2003, 24:343-349.
7. McHeyzer-Williams L.J., Driver D.J., McHeyzer-Williams M.G. Germinal center reaction. Curr Opin Hematol 2001, 8:52-59.
8. Shapiro-Shelef M., Calame K. Regulation of plasma-cell development. Nat Rev Immunol 2005, 5:230-242.
9. Fais F., Ghiotto F., Hashimoto S., Sellars B., Valetto A., Allen S.L., et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998, 102:1515-1525.
10. Schroeder H.W., Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today 1994, 15:288-294.
11. Damle R.N., Ghiotto F., Valetto A., Albesiano E., Fais F., Yan X.J., et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002, 99:4087-4093.
12. Stevenson F.K., Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004, 103:4389-4395.
13. Klein U., Tu Y., Stolovitzky G.A., Mattioli M., Cattoretti G., Husson H., et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001, 194:1625-1638.
14. Murray F., Darzentas N., Hadzidimitriou A., Tobin G., Boudjogra M., Scielzo C., et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 2008, 111:1524-1533.
15. Stamatopoulos K., Belessi C., Moreno C., Boudjograh M., Guida G., Smilevska T., et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007, 109:259-270.
16. Gahrton G., Robert K.H., Friberg K., Zech L., Bird A.G. Nonrandom chromosomal aberrations in chronic lymphocytic leukemia revealed by polyclonal B-cell-mitogen stimulation. Blood 1980, 56:640-647.
17. Oscier D.G. Cytogenetic and molecular abnormalities in chronic lymphocytic leukaemia. Blood Rev 1994, 8:88-97.
18. Dierlamm J., Michaux L., Criel A., Wlodarska I., Van den Berghe H., Hossfeld D.K. Genetic abnormalities in chronic lymphocytic leukemia and their clinical and prognostic implications. Cancer Genet Cytogenet 1997, 94:27-35.
19. Gardiner A.C., Corcoran M.M., Oscier D.G. Cytogenetic, fluorescence in situ hybridisation, and clinical evaluation of translocations with concomitant deletion at 13q14 in chronic lymphocytic leukaemia. Genes Chromosomes Cancer 1997, 20:73-81.
20. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002, 99:15524-15529.
21. Kitada S., Andersen J., Akar S., Zapata J.M., Takayama S., Krajewski S., et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood 1998, 91:3379-3389.
22. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005, 102:13944-13949.
23. Hamblin T.J. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 2006, 33:230-239.
24. Analo H.I., Akanmu A.S., Akinsete I., Njoku O.S., Okany C.C. Seroprevalence study of HTLV-1 and HIV infection in blood donors and patients with lymphoid malignancies in Lagos, Nigeria. Cent Afr J Med 1998, 44:130-134.
25. Cartwright R.A., Bernard S.M., Bird C.C., Darwin C.M., O'Brien C., Richards I.D., et al. Chronic lymphocytic leukaemia: case control epidemiological study in Yorkshire. Br J Cancer 1987, 56:79-82.
26. Landgren O., Pfeiffer R.M., Stewart L., Gridley G., Mellemkjaer L., Hemminki K., et al. Risk of second malignant neoplasms among lymphoma patients with a family history of cancer. Int J Cancer 2007, 120:1099-1102.
27. Landgren O., Rapkin J.S., Caporaso N.E., Mellemkjaer L., Gridley G., Goldin L.R., et al. Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia. Blood 2007, 109:2198-2201.
28. Yuille M.R., Matutes E., Marossy A., Hilditch B., Catovsky D., Houlston R.S. Familial chronic lymphocytic leukaemia: a survey and review of published studies. Br J Haematol 2000, 109:794-799.
29. Jonsson V., Houlston R.S., Catovsky D., Yuille M.R., Hilden J., Olsen J.H., et al. CLL family 'Pedigree 14' revisited: 1947-2004. Leukemia 2005, 19:1025-1028.
30. Linet M.S., Van Natta M.L., Brookmeyer R., Khoury M.J., McCaffrey L.D., Humphrey R.L., et al. Familial cancer history and chronic lymphocytic leukemia. A case-control study. Am J Epidemiol 1989, 130:655-664.
31. Goldin L.R., Pfeiffer R.M., Li X., Hemminki K. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-cancer database. Blood 2004, 104:1850-1854.
32. Gunz F.W., Gunz J.P., Veale A.M., Chapman C.J., Houston I.B. Familial leukaemia: a study of 909 families. Scand J Haematol 1975, 15:117-131.
33. Giles G.G., Lickiss J.N., Baikie M.J., Lowenthal R.M., Panton J. Myeloproliferative and lymphoproliferative disorders in Tasmania, 1972-80: occupational and familial aspects. J Natl Cancer Inst 1984, 72:1233-1240.
34. Goldgar D.E., Easton D.F., Cannon-Albright L.A., Skolnick M.H. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994, 86:1600-1608.
35. Pottern L.M., Linet M., Blair A., Dick F., Burmeister L.F., Gibson R., et al. Familial cancers associated with subtypes of leukemia and non-Hodgkin's lymphoma. Leuk Res 1991, 15:305-314.
36. Goldin L.R., Bjorkholm M., Kristinsson S.Y., Turesson I., Landgren O. Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia. Haematologica 2009, 94:647-653.
37. Ishibe N., Sgambati M.T., Fontaine L., Goldin L.R., Jain N., Weissman N., et al. Clinical characteristics of familial B-CLL in the National Cancer Institute Familial Registry. Leuk Lymphoma 2001, 42:99-108.
38. Crowther-Swanepoel D., Wild R., Sellick G., Dyer M.J., Mauro F.R., Cuthbert R.J., et al. Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL. Blood 2008, 111:5691-5693.
39. Wiernik P.H., Ashwin M., Hu X.P., Paietta E., Brown K. Anticipation in familial chronic lymphocytic leukaemia. Br J Haematol 2001, 113:407-414.
40. Horwitz M., Goode E.L., Jarvik G.P. Anticipation in familial leukemia. Am J Hum Genet 1996, 59:990-998.
41. Yuille M.R., Houlston R.S., Catovsky D. Anticipation in familial chronic lymphocytic leukaemia. Leukemia 1998, 12:1696-1698.
42. Daugherty S.E., Pfeiffer R.M., Mellemkjaer L., Hemminki K., Goldin L.R. No evidence for anticipation in lymphoproliferative tumors in population-based samples. Cancer Epidemiol Biomarkers Prev 2005, 14:1245-1250.
43. Mauro F.R., Giammartini E., Gentile M., Sperduti I., Valle V., Pizzuti A., et al. Clinical features and outcome of familial chronic lymphocytic leukemia. Haematologica 2006, 91:1117-1120.
44. Brezinschek H.P., Brezinschek R.I., Lipsky P.E. Analysis of the heavy chain repertoire of human peripheral B cells using single-cell polymerase chain reaction. J Immunol 1995, 155:190-202.
45. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., Stevenson F.K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94:1848-1854.
46. Mockridge C.I., Rahman A., Buchan S., Hamblin T., Isenberg D.A., Stevenson F.K., et al. Common patterns of B cell perturbation and expanded V4-34 immunoglobulin gene usage in autoimmunity and infection. Autoimmunity 2004, 37:9-15.
47. Kostareli E., Hadzidimitriou A., Stavroyianni N., Darzentas N., Athanasiadou A., Gounari M., et al. Molecular evidence for EBV and CMV persistence in a subset of patients with chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors. Leukemia 2009, 23:919-924.
48. Goldin L.R., Ishibe N., Sgambati M., Marti G.E., Fontaine L., Lee M.P., et al. A genome scan of 18 families with chronic lymphocytic leukaemia. Br J Haematol 2003, 121:866-873.
49. Sellick G.S., Goldin L.R., Wild R.W., Slager S.L., Ressenti L., Strom S.S., et al. A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. Blood 2007, 110:3326-3333.
50. Sellick G.S., Webb E.L., Allinson R., Matutes E., Dyer M.J., Jonsson V., et al. A high-density SNP genomewide linkage scan for chronic lymphocytic leukemia-susceptibility loci. Am J Hum Genet 2005, 77:420-429.
51. Fuller S.J., Papaemmanuil E., McKinnon L., Webb E., Sellick G.S., Dao-Ung L.P., et al. Analysis of a large multi-generational family provides insight into the genetics of chronic lymphocytic leukemia. Br J Haematol 2008, 142:238-245.
52. Raval A., Tanner S.M., Byrd J.C., Angerman E.B., Perko J.D., Chen S.S., et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 2007, 129:879-890.
53. Houlston R.S., Peto J. The future of association studies of common cancers. Hum Genet 2003, 112:434-435.
54. Di Bernardo M.C., Crowther-Swanepoel D., Broderick P., Webb E., Sellick G., Wild R., et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet 2008, 40:1204-1210.
55. Crowther-Swanepoel D., Broderick P., Di Bernardo M.C., Dobbins S.E., Torres M., Mansouri M., et al. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet 2010, 42:132-136.
56. Slager S.L., Goldin L.R., Strom S.S., Lanasa M.C., Spector L.G., Rassenti L., et al. Genetic susceptibility variants for chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev 2010, 19:1098-1102.
57. Crowther-Swanepoel D., Mansouri M., Enjuanes A., Vega A., Smedby K.E., Ruiz-Ponte C., et al. Verification that common variation at 2q37.1, 6p25.3, 11q24.1, 15q23, and 19q13.32 influences chronic lymphocytic leukaemia risk. Br J Haematol 2010, 150:473-479.
58. Rawstron A.C., Green M.J., Kuzmicki A., Kennedy B., Fenton J.A., Evans P.A., et al. Monoclonal B lymphocytes with the characteristics of " indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood 2002, 100:635-639.
59. Rawstron A.C., Bennett F.L., O'Connor S.J., Kwok M., Fenton J.A., Plummer M., et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008, 359:575-583.
60. Marti G.E., Carter P., Abbasi F., Washington G.C., Jain N., Zenger V.E., et al. B-cell monoclonal lymphocytosis and B-cell abnormalities in the setting of familial B-cell chronic lymphocytic leukemia. Cytometry B Clin Cytom 2003, 52:1-12.
61. Rawstron A.C., Yuille M.R., Fuller J., Cullen M., Kennedy B., Richards S.J., et al. Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood 2002, 100:2289-2290.
62. Busslinger M. Transcriptional control of early B cell development. Annu Rev Immunol 2004, 22:55-79.
63. Klein U., Casola S., Cattoretti G., Shen Q., Lia M., Mo T., et al. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol 2006, 7:773-782.
64. Xu D., Zhao L., Del Valle L., Miklossy J., Zhang L. Interferon regulatory factor 4 is involved in Epstein-Barr virus-mediated transformation of human B lymphocytes. J Virol 2008, 82:6251-6258.
65. Adami J., Frisch M., Yuen J., Glimelius B., Melbye M. Evidence of an association between non-Hodgkin's lymphoma and skin cancer. BMJ 1995, 310:1491-1495.
66. Swerdlow A.J., Storm H.H., Sasieni P.D. Risks of second primary malignancy in patients with cutaneous and ocular melanoma in Denmark, 1943-1989. Int J Cancer 1995, 61:773-779.
67. Han J., Kraft P., Nan H., Guo Q., Chen C., Qureshi A., et al. A genome-wide association study identifies novel alleles associated with hair color and skin pigmentation. PLoS Genet 2008, 4:e1000074.
68. Pho L.N., Leachman S.A. Genetics of pigmentation and melanoma predisposition. G Ital Dermatol Venereol 2010, 145:37-45.
69. Bloch D.B., de la Monte S.M., Guigaouri P., Filippov A., Bloch K.D. Identification and characterization of a leukocyte-specific component of the nuclear body. J Biol Chem 1996, 271:29198-29204.
70. Dent A.L., Yewdell J., Puvion-Dutilleul F., Koken M.H., de The H., Staudt L.M. LYSP100-associated nuclear domains (LANDs): description of a new class of subnuclear structures and their relationship to PML nuclear bodies. Blood 1996, 88:1423-1426.
71. Ling P.D., Peng R.S., Nakajima A., Yu J.H., Tan J., Moses S.M., et al. Mediation of Epstein-Barr virus EBNA-LP transcriptional coactivation by Sp100. EMBO J 2005, 24:3565-3575.
72. Madani N., Millette R., Platt E.J., Marin M., Kozak S.L., Bloch D.B., et al. Implication of the lymphocyte-specific nuclear body protein Sp140 in an innate response to human immunodeficiency virus type 1. J Virol 2002, 76:11133-11138.
73. Page-McCaw P.S., Amonlirdviman K., Sharp P.A. PUF60: a novel U2AF65-related splicing activity. RNA 1999, 5:1548-1560.
74. Duncan R., Bazar L., Michelotti G., Tomonaga T., Krutzsch H., Avigan M., et al. A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. Genes Dev 1994, 8:465-480.
75. Liu J., He L., Collins I., Ge H., Libutti D., Li J., et al. The FBP interacting repressor targets TFIIH to inhibit activated transcription. Mol Cell 2000, 5:331-341.
76. Kovalevska L.M., Yurchenko O.V., Shlapatska L.M., Berdova G.G., Mikhalap S.V., Van Lint J., et al. Immunohistochemical studies of protein kinase D (PKD) 2 expression in malignant human lymphomas. Exp Oncol 2006, 28:225-230.
77. Miyamoto Y., Yamauchi J., Itoh H. Src kinase regulates the activation of a novel FGD-1-related Cdc42 guanine nucleotide exchange factor in the signaling pathway from the endothelin A receptor to JNK. J Biol Chem 2003, 278:29890-29900.
78. Ikeda M., Longnecker R. The c-Cbl proto-oncoprotein downregulates EBV LMP2A signaling. Virology 2009, 385:183-191.
79. Gudmundsson J., Sulem P., Manolescu A., Amundadottir L.T., Gudbjartsson D., Helgason A., et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007, 39:631-637.
80. Easton D.F., Pooley K.A., Dunning A.M., Pharoah P.D., Thompson D., Ballinger D.G., et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007, 447:1087-1093.
81. Tomlinson I., Webb E., Carvajal-Carmona L., Broderick P., Kemp Z., Spain S., et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet 2007, 39:984-988.
82. Yeager M., Orr N., Hayes R.B., Jacobs K.B., Kraft P., Wacholder S., et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007, 39:645-649.
83. Amundadottir L.T., Sulem P., Gudmundsson J., Helgason A., Baker A., Agnarsson B.A., et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006, 38:652-658.
84. Kiemeney L.A., Thorlacius S., Sulem P., Geller F., Aben K.K., Stacey S.N., et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet 2008, 40:1307-1312.
85. Pomerantz M.M., Ahmadiyeh N., Jia L., Herman P., Verzi M.P., Doddapaneni H., et al. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet 2009, 41:882-884.
86. Shaffer A.L., Emre N.C., Lamy L., Ngo V.N., Wright G., Xiao W., et al. IRF4 addiction in multiple myeloma. Nature 2008, 454:226-231.